Coronavirus Pandemic
Logo
 

India's Zydus Cadila seeks for emergency use nod for Covid-19 vaccine

Reuters/Bengaluru
Filed on July 1, 2021 | Last updated on July 1, 2021 at 07.40 am

ZyCoV-D showed safety and efficacy in trial with more than 28,000 volunteers, including about 1,000 subjects in the 12-18 year age group.


Indian drugmaker Zydus Cadila said on Thursday it has applied to the country’s drug regulator for emergency use approval of its Covid-19 vaccine and that it plans to manufacture up to 120 million doses of the shot annually.

Coronavirus cases in India dropped from a devastating peak in April and May, however, experts have warned of a third wave and reiterated that widespread vaccination remains one of the best defences against the pandemic.

An approval for Zydus’ vaccine, ZyCoV-D, would make it the fifth vaccine authorized for use in India, after Moderna, AstraZeneca and partner Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, and Sputnik V developed by Russia’s Gamaleya Institute.

ZyCoV-D showed safety and efficacy in a late-stage trial with more than 28,000 volunteers across the country, including about 1,000 subjects in the 12-18 year age group, Zydus said.

The study was carried out “during the peak of second wave of Covid-19 (in India), reaffirming the vaccine’s efficacy against the new mutant strains especially the Delta variant,” Zydus said in a statement to the stock exchanges.





ERROR: Macro /ads/dfp-ad-article-new is missing!
MORE FROM Coronavirus Pandemic
MORE FROM Khaleej Times
CurrentRequestUnmodified: /apps/pbcs.dll/article?avis=KT&date=20200813&category=ARTICLE&lopenr=200819581&Ref=AR&profile=1913 macro_action: article, macro_profile: ,1913,1000 macro_adspot:
 
 
 
 
 
KT App Download
khaleejtimes app

All new KT app
is available
for download:

khaleejtimes - android khaleejtimes - ios khaleejtimes - HUAWEI AppGallery